Drugs / MAGE-C2.A2
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00365937 | Aug 2006 → Dec 2013 | cutaneous melanoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
| Phase 1/2 | NCT00145158 | Jan 2005 → Nov 2007 | melanoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAGE-C2.A2 | “These peptides are the following: MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2 (ALKD), and NA17.A2 (20% intradermally and 80% subcutaneously); NY-ESO-1.A2 and...” NCT00145158 ↗1“MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks” NCT00365937 ↗ |
| Known as | ALKD | “These peptides are the following: MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2 (ALKD), and NA17.A2 (20% intradermally and 80% subcutaneously); NY-ESO-1.A2 and...” NCT00145158 ↗ |
| Modality | Peptide | “The eight HLA-A2 peptides” NCT00365937 ↗ |